NASDAQ:CNSP - CNS Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 593.07 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.01
▲ +0.02 (2.02%)

This chart shows the closing price for CNSP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CNS Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNSP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNSP

Analyst Price Target is $7.00
▲ +593.07% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for CNS Pharmaceuticals in the last 3 months. The average price target is $7.00, with a high forecast of $10.00 and a low forecast of $4.00. The average price target represents a 593.07% upside from the last price of $1.01.

This chart shows the closing price for CNSP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in CNS Pharmaceuticals. This rating has held steady since January 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/14/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/13/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/9/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/8/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/27/2021Alliance Global PartnersInitiated CoverageBuy$4.00High
2/2/2021Brookline Capital ManagementInitiated CoverageBuy$10.00Low
12/28/2020LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralN/A
8/24/2020LADENBURG THALM/SH SHInitiated CoverageBuy$11.00High
12/4/2019BenchmarkInitiated CoverageSpeculative BuyMedium
(Data available from 12/9/2016 forward)

News Sentiment Rating

0.73 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/13/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/12/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/11/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/10/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
10/10/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2021

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
CNS Pharmaceuticals logo
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was founded in 2017 and is based in Houston, Texas.
Read More

Today's Range

Now: $1.01
Low: $0.98
High: $1.02

50 Day Range

MA: $1.29
Low: $0.94
High: $1.54

52 Week Range

Now: $1.01
Low: $0.89
High: $4.46

Volume

68,780 shs

Average Volume

677,158 shs

Market Capitalization

$28.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.21

Frequently Asked Questions

What sell-side analysts currently cover shares of CNS Pharmaceuticals?

The following sell-side analysts have issued stock ratings on CNS Pharmaceuticals in the last twelve months: Alliance Global Partners, Brookline Capital Management, LADENBURG THALM/SH SH, and Zacks Investment Research.
View the latest analyst ratings for CNSP.

What is the current price target for CNS Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for CNS Pharmaceuticals in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 593.1%. Brookline Capital Management has the highest price target set, predicting CNSP will reach $10.00 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $4.00 for CNS Pharmaceuticals in the next year.
View the latest price targets for CNSP.

What is the current consensus analyst rating for CNS Pharmaceuticals?

CNS Pharmaceuticals currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CNSP will outperform the market and that investors should add to their positions of CNS Pharmaceuticals.
View the latest ratings for CNSP.

How do I contact CNS Pharmaceuticals' investor relations team?

CNS Pharmaceuticals' physical mailing address is 2100 WEST LOOP SOUTH SUITE 900, HOUSTON TX, 77027. The company's listed phone number is 800-946-9185 and its investor relations email address is [email protected] The official website for CNS Pharmaceuticals is www.cnspharma.com.